MDM2 SNP309 genotype influences survival of metastatic but not of localized neuroblastoma
| Autor: | Gian Paolo Tonini, R. Defferrari, Riccardo Haupt, Stefano Parodi, Giovanna Bianchi Scarrà, Chiara Perfumo, Alberto Inga, Paola Ghiorzo, Gilberto Fronza, Katia Mazzocco |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Oncology
medicine.medical_specialty education.field_of_study biology business.industry Population Hematology medicine.disease Polymorphism (computer science) Internal medicine Neuroblastoma Pediatrics Perinatology and Child Health Gene expression Cohort Immunology Genotype medicine biology.protein Mdm2 Stage (cooking) education business neoplasms |
| Zdroj: | Pediatric Blood & Cancer. 53:576-583 |
| ISSN: | 1545-5009 |
| DOI: | 10.1002/pbc.22132 |
| Popis: | Background MDM2 is a major negative regulator of p53 function and is directly regulated by MYCN in neuroblastoma (NB) cells. MDM2 SNP309, a T-to-G substitution in the MDM2 promoter associated with higher gene expression compared to wild-type, may attenuate the p53 pathway in NB, in which p53 mutations are rare. We investigated its impact on NB development and survival in relation with major clinical and biological characteristics. Procedure A consecutive cohort of 497 NB children, diagnosed in Italy between 1995 and 2005, and a healthy control population of 471 adults were genotyped for MDM2 SNP309. NB patients were followed up until June 30, 2008. Results Patients and controls showed similar distribution of MDM2 SNP309 genotypes. In patients, the polymorphism was not associated with any characteristic at diagnosis. In localized stages no effect of the polymorphism on survival was evident. In stage 4 patients overall survival (OS), event free survival (EFS) and survival after relapse (SAR) were significantly poorer for TG/GG than for TT patients (P = 0.008; P = 0.013; P = 0.046, respectively). In this group, such an effect was more evident in patients with MYCN amplification (OS: P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text